Europe secures first contracts for flu pandemic

As part of the response to a pandemic emergency, UK-based flu prevention specialist, Seqirus, has signed contracts with the European Commission and 15 EU Member States to supply flu vaccines.

The company is the first influenza vaccine manufacturer to sign pandemic contracts under the EU joint procurement framework.

A pandemic occurs when an influenza virus which was not previously circulating among humans and to which most people don’t have immunity emerges and transmits among humans.

As the majority of the population has no immunity to these viruses, an outbreak can result in significant morbidity and mortality.

The European Centre for Disease Prevention and Control estimates that a severe pandemic could infect up to a quarter of the population of the EU, with many millions of cases and tens of thousands of deaths.

“According to the WHO, influenza remains one of the world’s greatest public health challenges and the question is not whether we will have another pandemic, but when,” said Gordon Naylor, President of Seqirus.

“We are committed to working with our partners to protect people around the world by providing rapid access to influenza vaccines during a pandemic emergency.”

The development of the EU joint procurement framework was driven by the H1N1 influenza pandemic in 2009, which highlighted the lack of consistency in access to pandemic vaccines between EU countries.

The WHO’s Global Influenza Strategy for 2019 – 2030 states that a severe pandemic can result in widespread social and economic effects, including a loss of national economic productivity and severe economic burdens on affected citizens and communities.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...